Sunshine Biopharma
SBFM
3 hedge funds and large institutions have $3.55M invested in Sunshine Biopharma in 2022 Q1 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
8.9% more ownership
Funds ownership: 0% → 8.9% (+8.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$1.95M |
| 2 |
Empery Asset Management
New York
|
+$974K |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$974K |
Top Sellers
SBFM Hedge Fund Activity: Q1 2022 in Review
3 of the 6,363 institutional investors tracked by Wall St. Rank reported a position in Sunshine Biopharma (SBFM) for Q1 2022, worth a combined $3.55M.
Buyers outnumbered sellers: 3 funds opened new SBFM positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.95M.
- 3 institutional investors held Sunshine Biopharma (SBFM) as of Q1 2022, up from 0 in Q4 2021.
- Funds reported $3.55M of Sunshine Biopharma stock for Q1 2022.
- 3 funds opened new Sunshine Biopharma positions in Q1 2022 and 0 closed out, a net change of +3 holders.
- The largest Sunshine Biopharma buyer in Q1 2022 was Armistice Capital, an estimated $1.95M added.
Based on aggregated 13F filings for Q1 2022.